Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial. Nov 2011 - J Transl Med; 9:1479-5876 [PMID:22013914] [Baek S] [Kim CS] [Kim SB] [Kim YM] [Kwon SW] [Kim Y] [Kim H] [Lee H]
Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. Mai 2011 - PLoS ONE; 6(4):1932-6203 [PMID:21533099] [Draube A] [Klein-González N] [Mattheus S] [Brillant C] [Hellmich M] [Engert A] [von Bergwelt-Baildon M]
Chemokine-mediated distribution of dendritic cell subsets in renal cell carcinoma. Nov 2010 - BMC Cancer; 10:1471-2407 [PMID:20969772] [Middel P] [Brauneck S] [Meyer W] [Radzun HJ]
Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2. Apr 2010 - J. Immunother.; 33(4):1537-4513 [PMID:20386464] [Berntsen A] [Brimnes MK] [thor Straten P] [Svane IM]
Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate. Okt 2009 - Scand. J. Immunol.; 70(5):1365-3083 [PMID:19874553] [Soleimani A] [Berntsen A] [Svane IM] [Pedersen AE]
Vaccine therapy in patients with renal cell carcinoma. Jul 2009 - Eur. Urol.; 55(6):1873-7560 [PMID:19201522] [Van Poppel H] [Joniau S] [Van Gool SW]
Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer. Jul 2009 - Int. J. Oncol.; 35(3):1019-6439 [PMID:19639177] [Lemoine FM] [Cherai M] [Giverne C] [Dimitri D] [Rosenzwajg M] [Trebeden-Negre H] [Chaput N] [Barrou B] [Thioun N] [Gattegnio B] [Selles F] [Six A] [Azar N] [Lotz JP] [Buzyn A] [Sibony M] [Delcourt A] [Boyer O] [Herson S] [Klatzmann D] [Lacave R]
Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses. Jul 2009 - Cancer Immunol. Immunother.; 58(10):1432-0851 [PMID:19221746] [Zhou J] [Weng D] [Zhou F] [Pan K] [Song H] [Wang Q] [Wang H] [Wang H] [Li Y] [Huang L] [Zhang H] [Huang W] [Xia J]
Vaccination strategies in patients with renal cell carcinoma. Apr 2009 - Cancer Immunol. Immunother.; 58(7):1432-0851 [PMID:19360405] [Asemissen AM] [Brossart P]
Vaccination with transforming growth factor-beta insensitive dendritic cells suppresses pulmonary metastases of renal carcinoma in mice. Okt 2008 - Cancer Lett.; 271(2):1872-7980 [PMID:18675506] [Tian F] [Wang L] [Qin W] [Wang F] [Song B] [Li Y] [Wen W] [Zhang Z] [Zhu K] [Zhang Q] [Lee C] [Zhong W] [Guo Y] [Wang H]
Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial. Sep 2008 - J. Immunother.; 31(8):1537-4513 [PMID:18779742] [Berntsen A] [Trepiakas R] [Wenandy L] [Geertsen PF] [thor Straten P] [Andersen MH] [Pedersen AE] [Claesson MH] [Lorentzen T] [Johansen JS] [Svane IM]
Dendritic cell therapy in combination with interferon-alpha for the treatment of metastatic renal cell carcinoma. Sep 2008 - Int. J. Urol.; 15(8):1442-2042 [PMID:18564205] [Tatsugami K] [Eto M] [Harano M] [Hamaguchi M] [Miyamoto T] [Morisaki T] [Furue M] [Akashi K] [Naito S]
Delivery of whole tumor lysate into dendritic cells for cancer vaccination. Apr 2008 - Methods Mol. Biol.; 423:1064-3745 [PMID:18370195] [Liu LN] [Shivakumar R] [Allen C] [Fratantoni JC]
Apoptic renal carcinoma cells are better inducers of cross-presenting activity than their primary necrotic counterpart. Jan 2008 - Int J Immunopathol Pharmacol; 20(4):0394-6320 [PMID:18179743] [D' Hooghe E] [Buttiglieri S] [Bisignano G] [Brusa D] [Camussi G] [Matera L]
Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. Nov 2007 - Clin. Immunol.; 125(3):1521-6616 [PMID:17916447] [Kim JH] [Lee Y] [Bae YS] [Kim WS] [Kim K] [Im HY] [Kang WK] [Park K] [Choi HY] [Lee HM] [Baek SY] [Lee H] [Doh H] [Kim BM] [Kim CY] [Jeon C] [Jung CW]
